Overall survival (OS) for patients with metastatic colorectal cancer (mCRC) has markedly improved within the last 2 decades and the most recent generation of randomized clinical trials have yielded median OS durations of 30 months or longer.[1–3] Reasons for this improvement are numerous and multifactorial, although three main points are considered to be the most relevant:
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pMnoWo
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
http://orl-agios.blogspot.com/2017/06/the-preclinical-anticancer-effect-of.html Flavonoids present in foods were considered non-absorbable b...
-
World Community; and Remarks on our Own Behalf Models of Anticipation Within the Responsible Research and Innovation Framework: the Two RRI ...
-
Vol.31 No.5 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1k8FKtW via IFTTT
-
Radioterapia oncologica, la Cattolica protagonista al Congresso Europeo insalutenews ... l'utilizzo della radioterapia stereotass...
-
Publication date: Available online 24 December 2017 Source: European Journal of Radiology Author(s): Wenbin Jiang, Hongwei Xue, Qinqin W...
-
Related Articles Promoting the Inclusion of Lung Volumes in the Reversibility Evaluation-Reply. Respir Care. 2017 Feb;62(2):256 Auth...
-
Geographic region: Does it matter in cutaneous melanoma of the head and neck? Laryngoscope. 2017 Jun 05;: Authors: Kılıç S, Unsal AA,...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου